<DOC>
	<DOCNO>NCT00881101</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose dose limit toxicity liposomal paclitaxel Chinese patient solid tumor advance stage .</brief_summary>
	<brief_title>Clinical Study Liposomal Paclitaxel Chinese Patients</brief_title>
	<detailed_description>There clinical trial show paclitaxel common option treatment solid tumor . Liposomal paclitaxel different pharmacokinetic feature compare conventional paclitaxel . However , tolerance new dosage form paclitaxel ( liposomal paclitaxel ) never study Chinese cancer patient . This study design find maximum tolerate dose dose limit toxicity liposomal paclitaxel Chinese cancer patient .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Age : 18 70 2 . Patients solid tuomors advance stage must histologically cytologically confirm , suitable treat Paclitaxel Liposome solo 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 4 . Patients expect live least 3 month 5 . Laboratory test study : white blood count ( WBC ) ≥4,000/mm³ , absolute neutrophil count ( ANC ) ≥1,500/mm³ , platelet count ≥100,000/mm³ , hemoglobin≥9.0 g/dL , aspartate aminotransferase AST ( sGOT ) alanine aminotransferase ALT ( sGPT ) ≤2.5 time normal value upper limit，serum creatinine≤1.0 time normal value upper limit，total bilirubin≤1.5 time normal value upper limit 6 . Not use chemotherapeutics ( include test drug ) study trial least 4 week 7 . No obvious functional disturbance disease internal organ 8 . Complying study protocol 9 . Sign inform consent 10 . No Previous anaphylactic reaction hormone 1 . Allergy medication food ; History hypersensitivity reaction conventional dosage form paclitaxel correlate excipients 2 . Active uncontrolled central nervous system metastasis 3 . Severe complication obviously influence compliance patient 4 . Grade ≥1 neuropathy use NCI CTCAE version 3.0 criterion 5 . Taking study medication participate clinical trial within 4w 6 . Having radiation therapy operation within 4w 7 . Any nonremission toxicity ≥ CTC 1 prior anticancer therapy ( include radiation therapy ) ( except alopecie hemoglobin ) 8 . Pregnant lactant woman ; fertile patient use effective contraception study 9 . No chief organ functional disturbance disease : abnormal liver renal function myocardial infarction active heart disease neuropathy mental disease include dementia epilepsy blind、deaf、dumb extremity disability know infection active diffuse intravascular coagulation 10 . Others researcher regard eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Liposomal Paclitaxel</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Dose limit toxicity</keyword>
</DOC>